{
    "info": {
        "nct_id": "NCT03250273",
        "official_title": "A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma",
        "inclusion_criteria": "1. Age ≥18 years.\n2. Have histologically or cytologically proven cholangiocarcinoma or adenocarcinoma of the pancreas that is metastatic or unresectable.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n4. Life expectancy of greater than 12 weeks.\n5. Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n6. Woman of child bearing potential must have a negative pregnancy test.\n7. Must have progressive measurable disease.\n8. Must have an accessible non-bone tumor that can be biopsied.\n9. Must use acceptable form of birth control while on study.\n10. Willing to provide tissue and blood samples.\n11. Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Chemotherapy, radiotherapy, investigational therapy, or surgery less than 3 weeks prior to trial registration\n2. Prior treatment with epigenetic therapy (such as entinostat, panobinostat, vorinostat, romidepsin, 5-azacitidine, or decitabine)\n3. Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.).\n4. Hypersensitivity reaction to any monoclonal antibody.\n5. History of any autoimmune disease: inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis). Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event).\n6. Have significant and/or malignant pleural effusion\n7. Has a pulse oximetry < 92% on room air.\n8. Known history or evidence of brain metastases.\n9. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.\n10. Are pregnant or breastfeeding.\n11. Infection with HIV or hepatitis B or C.\n12. Patients on immunosuppressive agents.\n13. Requiring concurrent administration of valproic acid.\n14. Patients with diverticulitis, intra-abdominal abscess, or GI obstruction\n15. Any contraindication to oral agents.\n16. Another active malignancy ≤ 3 years prior to registration with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type.\n17. Unwilling or unable to follow the study schedule for any reason.\n18. Evidence of ascites on imaging.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Age ≥18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Have histologically or cytologically proven cholangiocarcinoma or adenocarcinoma of the pancreas that is metastatic or unresectable.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically proven cholangiocarcinoma",
                    "criterion": "cholangiocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histologically proven",
                                "cytologically proven"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "adenocarcinoma of the pancreas",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histologically proven",
                                "cytologically proven"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that is metastatic or unresectable",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "metastatic",
                                "unresectable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Life expectancy of greater than 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of greater than 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Patients must have adequate organ and marrow function defined by study-specified laboratory tests.",
            "criterions": [
                {
                    "exact_snippets": "adequate organ and marrow function defined by study-specified laboratory tests",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "study-specified laboratory tests"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Woman of child bearing potential must have a negative pregnancy test.",
            "criterions": [
                {
                    "exact_snippets": "Woman of child bearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Must have progressive measurable disease.",
            "criterions": [
                {
                    "exact_snippets": "progressive measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressive"
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Must have an accessible non-bone tumor that can be biopsied.",
            "criterions": [
                {
                    "exact_snippets": "accessible non-bone tumor that can be biopsied",
                    "criterion": "non-bone tumor",
                    "requirements": [
                        {
                            "requirement_type": "accessibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "biopsy capability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Must use acceptable form of birth control while on study.",
            "criterions": [
                {
                    "exact_snippets": "Must use acceptable form of birth control while on study.",
                    "criterion": "birth control use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "acceptable"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "while on study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Willing to provide tissue and blood samples.",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide tissue",
                    "criterion": "tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing to provide ... blood samples",
                    "criterion": "blood sample",
                    "requirements": [
                        {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Ability to understand and willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "9. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.",
            "criterions": [
                {
                    "exact_snippets": "alcohol or drug dependence",
                    "criterion": "alcohol or drug dependence",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lack of sufficient peripheral venous access",
                    "criterion": "peripheral venous access",
                    "requirements": [
                        {
                            "requirement_type": "sufficiency",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Requiring concurrent administration of valproic acid.",
            "criterions": [
                {
                    "exact_snippets": "Requiring concurrent administration of valproic acid",
                    "criterion": "valproic acid administration",
                    "requirements": [
                        {
                            "requirement_type": "concurrent administration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Have significant and/or malignant pleural effusion",
            "criterions": [
                {
                    "exact_snippets": "significant and/or malignant pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "severity/type",
                            "expected_value": [
                                "significant",
                                "malignant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Hypersensitivity reaction to any monoclonal antibody.",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity reaction to any monoclonal antibody",
                    "criterion": "hypersensitivity reaction to monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Evidence of ascites on imaging.",
            "criterions": [
                {
                    "exact_snippets": "Evidence of ascites on imaging.",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Known history or evidence of brain metastases.",
            "criterions": [
                {
                    "exact_snippets": "Known history or evidence of brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Are pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior treatment with epigenetic therapy (such as entinostat, panobinostat, vorinostat, romidepsin, 5-azacitidine, or decitabine)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with epigenetic therapy (such as entinostat, panobinostat, vorinostat, romidepsin, 5-azacitidine, or decitabine)",
                    "criterion": "prior treatment with epigenetic therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "entinostat",
                                "panobinostat",
                                "vorinostat",
                                "romidepsin",
                                "5-azacitidine",
                                "decitabine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Patients on immunosuppressive agents.",
            "criterions": [
                {
                    "exact_snippets": "Patients on immunosuppressive agents",
                    "criterion": "immunosuppressive agent use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Patients with diverticulitis, intra-abdominal abscess, or GI obstruction",
            "criterions": [
                {
                    "exact_snippets": "Patients with diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intra-abdominal abscess",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "GI obstruction",
                    "criterion": "gastrointestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Unwilling or unable to follow the study schedule for any reason.",
            "criterions": [
                {
                    "exact_snippets": "Unwilling or unable to follow the study schedule for any reason.",
                    "criterion": "ability and willingness to follow study schedule",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Another active malignancy ≤ 3 years prior to registration with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type.",
            "criterions": [
                {
                    "exact_snippets": "Another active malignancy ≤ 3 years prior to registration",
                    "criterion": "active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type",
                    "criterion": "type of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "non-melanotic skin cancer",
                                "carcinoma-in-situ of any type"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Any contraindication to oral agents.",
            "criterions": [
                {
                    "exact_snippets": "Any contraindication to oral agents.",
                    "criterion": "contraindication to oral agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Chemotherapy, radiotherapy, investigational therapy, or surgery less than 3 weeks prior to trial registration",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... less than 3 weeks prior to trial registration",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy ... less than 3 weeks prior to trial registration",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "investigational therapy ... less than 3 weeks prior to trial registration",
                    "criterion": "investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "surgery less than 3 weeks prior to trial registration",
                    "criterion": "surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Has a pulse oximetry < 92% on room air.",
            "criterions": [
                {
                    "exact_snippets": "pulse oximetry < 92% on room air",
                    "criterion": "pulse oximetry",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.).",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.)",
                    "criterion": "prior treatment with immunotherapy agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "immunotherapy agents",
                                "anti-PD-1",
                                "anti-PD-L1",
                                "anti-PD-L2",
                                "anti-CTLA4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. History of any autoimmune disease: inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis). Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event).",
            "criterions": [
                {
                    "exact_snippets": "History of any autoimmune disease: inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis)",
                    "criterion": "history of autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)",
                    "criterion": "specific autoimmune conditions (vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "11. Infection with HIV or hepatitis B or C.",
            "criterions": [
                {
                    "exact_snippets": "Infection with HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}